Tumor Biology

, Volume 35, Issue 10, pp 9993–9997 | Cite as

miR-141 targets ZEB2 to suppress HCC progression

  • Shi-Min Wu
  • Hong-Wu Ai
  • Ding-Yu Zhang
  • Xiao-Qun Han
  • Qin Pan
  • Feng-Ling Luo
  • Xiao-Lian Zhang
Research Article


Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related deaths worldwide. Increasing evidence suggests that microRNAs (miRNAs) are associated with HCC tumorigenesis. The present study was designed to define the role of miR-141 in HCC. The expression of miR-141 was significantly decreased in four HCC cell lines. Overexpression of miR-141 suppressed both the growth and the motility of HCC cells. Furthermore, we identified zinc finger E-box binding homeobox 2 (ZEB2) as a target of miR-141 and miR-141 functioned as a tumor suppressor via ZEB2 targeting in HCC. These data provide a novel potential therapeutic target for HCC treatment.


HCC miR-141 ZEB2 Growth Motility 



This work was funded by the Open Research Fund Program of the State Key Laboratory of Virology of China (2013003) and the Natural Science Foundation of Hubei Province (2010CDB08201).

Conflicts of interest



  1. 1.
    Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.CrossRefPubMedGoogle Scholar
  2. 2.
    Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet. 2003;362:1907–17.CrossRefPubMedGoogle Scholar
  3. 3.
    Aravalli RN, Steer CJ, Cressman EN. Molecular mechanisms of hepatocellular carcinoma. Hepatology. 2008;48:2047–63.CrossRefPubMedGoogle Scholar
  4. 4.
    Lee CH, Kim JH, Lee SW. The role of microRNAs in hepatitis c virus replication and related liver diseases. J Microbiol. 2014;52:445–51.CrossRefPubMedGoogle Scholar
  5. 5.
    D'Anzeo M, Faloppi L, Scartozzi M, Giampieri R, Bianconi M, Del Prete M, et al. The role of micro-RNAs in hepatocellular carcinoma: from molecular biology to treatment. Molecules. 2014;19:6393–406.CrossRefPubMedGoogle Scholar
  6. 6.
    Shaikh F, Goff LW. Decoding hepatocellular carcinoma: the promise of microRNAs. Hepatobiliary Surgery Nutrition. 2014;3:93–4.PubMedCentralPubMedGoogle Scholar
  7. 7.
    Zhang Z, Zheng W, Hai J. MicroRNA-148b expression is decreased in hepatocellular carcinoma and associated with prognosis. Med Oncol. 2014;31:984.CrossRefPubMedGoogle Scholar
  8. 8.
    Liu YX, Long XD, Xi ZF, Ma Y, Huang XY, Yao JG, et al. MicroRNA-24 modulates aflatoxin b1-related hepatocellular carcinoma prognosis and tumorigenesis. Bio Med Research International. 2014;2014:482926.Google Scholar
  9. 9.
    9 Parpart S, Roessler S, Dong F, Rao V, Takai A, Ji J, Qin LX, Ye QH, Jia HL, Tang ZY, Wang XW: Modulation of mir-29 expression by alpha-fetoprotein is linked to the hepatocellular carcinoma epigenome. Hepatology 2014Google Scholar
  10. 10.
    10 Jiang HL, Yu H, Ma X, Xu D, Lin GF, Ma DY, Jin JZ: MicroRNA-195 regulates steroid receptor coactivator-3 protein expression in hepatocellular carcinoma cells. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 2014Google Scholar
  11. 11.
    11 Sheng Y, Li J, Zou C, Wang S, Cao Y, Zhang J, Huang A, Tang H: Downregulation of mir-101-3p by hepatitis b virus promotes proliferation and migration of hepatocellular carcinoma cells by targeting rab5a. Archives of virology 2014Google Scholar
  12. 12.
    Li Y, Liang C, Ma H, Zhao Q, Lu Y, Xiang Z, et al. Mir-221/222 promotes s-phase entry and cellular migration in control of basal-like breast cancer. Molecules. 2014;19:7122–37.CrossRefPubMedGoogle Scholar
  13. 13.
    Xu X, Wu J, Li S, Hu Z, Xu X, Zhu Y, et al. Downregulation of microRNA-182-5p contributes to renal cell carcinoma proliferation via activating the akt/foxo3a signaling pathway. Mol Cancer. 2014;13:109.PubMedCentralCrossRefPubMedGoogle Scholar
  14. 14.
    Zhang L, Dong Y, Zhu N, Tsoi H, Zhao Z, Wu CW, et al. MicroRNA-139-5p exerts tumor suppressor function by targeting notch1 in colorectal cancer. Mol Cancer. 2014;13:124.PubMedCentralCrossRefPubMedGoogle Scholar
  15. 15.
    Zhou J, Lu S, Yang S, Chen H, Shi H, Miao M, et al. MicroRNA-127 post-transcriptionally downregulates sept7 and suppresses cell growth in hepatocellular carcinoma cells. Cellular physiology and biochemistry. Int J Experimental Cellular Physiol, Biochem, Pharmacol. 2014;33:1537–46.CrossRefGoogle Scholar
  16. 16.
    Zheng Q, Sheng Q, Jiang C, Shu J, Chen J, Nie Z, et al. MicroRNA-452 promotes tumorigenesis in hepatocellular carcinoma by targeting cyclin-dependent kinase inhibitor 1b. Mol Cell Biochem. 2014;389:187–95.CrossRefPubMedGoogle Scholar
  17. 17.
    17 Wang W, Lin H, Zhou L, Zhu Q, Gao S, Xie H, Liu Z, Xu Z, Wei J, Huang X, Zheng S: MicroRNA-30a-3p inhibits tumor proliferation, invasiveness and metastasis and is downregulated in hepatocellular carcinoma. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 2013Google Scholar
  18. 18.
    Yang X, Zhang XF, Lu X, Jia HL, Liang L, Dong QZ, et al. MicroRNA-26a suppresses angiogenesis in human hepatocellular carcinoma by targeting hepatocyte growth factor-cmet pathway. Hepatology. 2014;59:1874–85.CrossRefPubMedGoogle Scholar
  19. 19.
    Li Q, Ding C, Chen C, Zhang Z, Xiao H, Xie F, et al. Mir-224 promotion of cell migration and invasion by targeting homeobox d 10 gene in human hepatocellular carcinoma. J Gastroenterol Hepatol. 2014;29:835–42.CrossRefPubMedGoogle Scholar
  20. 20.
    20 Banno K, Yanokura M, Iida M, Adachi M, Nakamura K, Nogami Y, Umene K, Masuda K, Kisu I, Nomura H, Kataoka F, Tominaga E, Aoki D: Application of microrna in diagnosis and treatment of ovarian cancer. BioMed research international 2014;2014:232817.Google Scholar
  21. 21.
    Diaz T, Tejero R, Moreno I, Ferrer G, Cordeiro A, Artells R, et al. Role of mir-200 family members in survival of colorectal cancer patients treated with fluoropyrimidines. J Surg Oncol. 2014;109:676–83.CrossRefPubMedGoogle Scholar
  22. 22.
    Chen B, Huang T, Jiang J, Lv L, Li H, Xia S. Mir-141 suppresses proliferation and motility of gastric cancer cells by targeting hdgf. Mol Cell Biochem. 2014;388:211–8.CrossRefPubMedGoogle Scholar
  23. 23.
    Chen X, Wang X, Ruan A, Han W, Zhao Y, Lu X, et al. Mir-141 is a key regulator of renal cell carcinoma proliferation and metastasis by controlling epha2 expression. Clin Cancer Res : an Off J Am Assoc Cancer Research. 2014;20:2617–30.CrossRefGoogle Scholar
  24. 24.
    Liu Y, Ding Y, Huang J, Wang S, Ni W, Guan J, et al. Mir-141 suppresses the migration and invasion of HCC cells by targeting tiam1. PLoS One. 2014;9:e88393.PubMedCentralCrossRefPubMedGoogle Scholar
  25. 25.
    Browne G, Sayan AE, Tulchinsky E. Zeb proteins link cell motility with cell cycle control and cell survival in cancer. Cell Cycle. 2010;9:886–91.CrossRefPubMedGoogle Scholar
  26. 26.
    26 Techasen A, Namwat N, Loilome W, Duangkumpha K, Puapairoj A, Saya H, Yongvanit P: Tumor necrosis factor-alpha modulates epithelial mesenchymal transition mediators zeb2 and s100a4 to promote cholangiocarcinoma progression. Journal of hepato-biliary-pancreatic sciences 2014Google Scholar
  27. 27.
    Sun Z, Zhang Z, Liu Z, Qiu B, Liu K, Dong G. MicroRNA-335 inhibits invasion and metastasis of colorectal cancer by targeting zeb2. Med Oncol. 2014;31:982.CrossRefPubMedGoogle Scholar
  28. 28.
    Guo F, Cogdell D, Hu L, Yang D, Sood AK, Xue F, et al. Mir-101 suppresses the epithelial-to-mesenchymal transition by targeting zeb1 and zeb2 in ovarian carcinoma. Oncol Rep. 2014;31:2021–8.PubMedCentralPubMedGoogle Scholar
  29. 29.
    You J, Li Y, Fang N, Liu B, Zu L, Chang R, et al. Mir-132 suppresses the migration and invasion of lung cancer cells via targeting the emt regulator zeb2. PLoS One. 2014;9:e91827.PubMedCentralCrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  • Shi-Min Wu
    • 1
    • 2
  • Hong-Wu Ai
    • 3
  • Ding-Yu Zhang
    • 2
  • Xiao-Qun Han
    • 2
  • Qin Pan
    • 1
  • Feng-Ling Luo
    • 1
  • Xiao-Lian Zhang
    • 1
  1. 1.State Key Laboratory of Virology, Department of Immunology, Hubei Province Key Laboratory of Allergy and Immunology, School of Basic Medical SciencesWuhan UniversityWuhanChina
  2. 2.Department of Clinical laboratoryWuhan Medical Treatment CenterWuhanChina
  3. 3.Department of Clinical laboratoryWuhan Medical and Health Center for Women and ChildrenWuhanChina

Personalised recommendations